Metelimumab Biosimilar – Anti-TGFB1 mAb – Research Grade

Description of Metelimumab Biosimilar - Anti-TGFB1 mAb - Research Grade

Introduction

Metelimumab Biosimilar, also known as Anti-TGFB1 mAb, is a research-grade monoclonal antibody that targets the transforming growth factor beta 1 (TGFB1) protein. This biosimilar has shown promising results in preclinical studies and is currently being developed as a potential therapeutic option for various diseases.

Structure

Metelimumab Biosimilar is a recombinant human IgG1 monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. It has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains are composed of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains have two constant domains (CL and CL’) and one variable domain (VL). The variable domains of the heavy and light chains come together to form the antigen-binding site, which specifically recognizes and binds to TGFB1.

Activity

TGFB1 is a multifunctional cytokine that plays a crucial role in cell growth, differentiation, and immune response. It is involved in various physiological processes, including wound healing, tissue repair, and embryonic development. However, dysregulation of TGFB1 has been linked to the pathogenesis of several diseases, such as cancer, fibrosis, and autoimmune disorders. Metelimumab Biosimilar binds to TGFB1 and inhibits its activity, thereby reducing the detrimental effects of excessive TGFB1 signaling.

Application

As a research-grade antibody, Metelimumab Biosimilar is primarily used in preclinical studies to investigate the role of TGFB1 in different diseases and to evaluate the potential therapeutic effects of targeting this cytokine. It has been shown to effectively block TGFB1 signaling in various in vitro and in vivo models, including cancer cell lines, animal models of fibrosis, and autoimmune disease models. This biosimilar has also been used in combination with other therapies to enhance their efficacy and improve treatment outcomes.

Therapeutic Target

The therapeutic target of Metelimumab Biosimilar is TGFB1, which is a key player in the pathogenesis of many diseases. By targeting this cytokine, this biosimilar has the potential to treat a wide range of conditions, including cancer, fibrosis, and autoimmune disorders. In cancer, TGFB1 promotes tumor growth, angiogenesis, and metastasis, and its inhibition by Metelimumab Biosimilar can suppress these processes and inhibit tumor progression. In fibrosis, TGFB1 is responsible for the excessive production of extracellular matrix, leading to tissue scarring and organ dysfunction. Metelimumab Biosimilar can prevent this fibrotic process and potentially reverse existing fibrosis. In autoimmune disorders, TGFB1 contributes to the development of autoimmune responses, and its inhibition by Metelimumab Biosimilar can help to control the overactive immune system and reduce disease symptoms.

Conclusion

In summary, Metelimumab Biosimilar is a research-grade monoclonal antibody that targets TGFB1 and has the potential to be developed as a therapeutic option for various diseases. Its unique structure and mechanism of action make it a promising candidate for the treatment of cancer, fibrosis, and autoimmune disorders. Further clinical studies are needed to fully evaluate the safety and efficacy of this biosimilar, but the initial preclinical data is promising and supports its potential as a valuable therapeutic tool.

Metelimumab Biosimilar - Anti-TGFB1 mAb binds to Human TGFB1/TGF-beta-1 in indirect ELISA Assay

Immobilized TGFB1 recombinant protein (cat. No. PX-P5187) at 0.5µg/mL (100µL/well) can bind Metelimumab Biosimilar - Anti-TGFB1 mAb (cat. No. PX-TA1138) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 133.8M.